Ultragenyx Pharmaceutical
RARE

$59.82

3.67%

Market Cap: $5.51B

About: Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Employees: 1,276

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 9 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 6 (+3) [Q2]

52% more call options, than puts

Call options by funds: $22.7M | Put options by funds: $15M

47% more repeat investments, than reductions

Existing positions increased: 116 | Existing positions reduced: 79

18% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 40

3% more funds holding

Funds holding: 264 [Q1] → 271 (+7) [Q2]

0.72% more ownership

Funds ownership: 96.64% [Q1] → 97.35% (+0.72%) [Q2]

2% less capital invested

Capital invested by funds: $3.71B [Q1] → $3.62B (-$88.5M) [Q2]

See Fund Rankings

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$45

25%

downside

Avg. target

$87

45%

upside

High target

$116

94%

upside

9 analyst ratings

7 positive

78%

2 neutral

22%

0 negative

0%

Cantor Fitzgerald Kristen Kluska 63% 1-year accuracy 51 / 81 met price target	94%upside $116	Overweight Reiterated	16 Sept 2024
Barclays Gena Wang 36% 1-year accuracy 8 / 22 met price target	35%upside $81	Overweight Maintained	5 Aug 2024
Wells Fargo Tiago Fauth 67% 1-year accuracy 8 / 12 met price target	25%upside $75	Overweight Maintained	2 Aug 2024
Goldman Sachs Salveen Richter 60% 1-year accuracy 12 / 20 met price target	27%upside $76	Buy Maintained	2 Aug 2024
Cantor Fitzgerald Kristen Kluska 63% 1-year accuracy 51 / 81 met price target	94%upside $116	Overweight Maintained	2 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about RARE published over the past 30 days

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 62,555 restricted stock units of the company's common stock to 16 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of September 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx to Participate in Investor Conferences in September

Morgan Stanley 22 nd Annual Global Healthcare Conference on September 4 Cantor Global Healthcare Conference on September 17 Bank of America Global Healthcare Conference on September 18 NOVATO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced participation in three upcoming investor conferences.

Ultragenyx to Participate in Investor Conferences in September

Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective

Ultragenyx develops therapies for rare genetic diseases, with a portfolio including Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company's promising pipeline targets severe diseases like osteogenesis imperfecta and Angelman syndrome, and it has progressed well in clinical trials. The company's financials show a strong cash position but a high P/B and P/S ratios, as well as significant future royalty liabilities on Crysvita.

Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 37,975 restricted stock units of the company's common stock to 12 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of August 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

3 Genomics Stocks That May Transform Personalized Medicine

When the human genome was fully sequenced in 2003, the prospects of genetic medicine ushered in a new era of human health. Today, scientists and drug developers have a better understanding of the genetic drivers of disease than ever before.

3 Genomics Stocks That May Transform Personalized Medicine

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2024 Earnings Call Transcript

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q2 2024 Earnings Conference Call August 1, 2024 5:00 PM ET Company Participants Joshua Higa - Vice President, Investor Relations Emil Kakkis - Chief Executive Officer & President Erik Harris - Chief Commercial Officer Howard Horn - Chief Financial Officer Eric Crombez - Chief Medical Officer Conference Call Participants Gena Wang - Barclays Salveen Richter - Goldman Sachs Dae Gon Ha - Stifel Tazeen Ahmad - Bank of America Kristen Kluska - Cantor Fitzgerald Joon Lee - Truist Maury Raycroft - Jefferies Will Soghikian - Leerink Partners Yaron Werber - TD Cowen Michael Riad - Morgan Stanley Jack Allen - Baird Lisa Walter - RBC Operator Good afternoon, and welcome to the Ultragenyx Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Ultragenyx (RARE) Q2 Loss Narrower Than Expected, Revenues Up

Ultragenyx (RARE) reports encouraging second-quarter 2024 results, beating both earnings and revenue estimates driven by the year-over-year increase of Crysvita and Dojolvi sales.

Ultragenyx (RARE) Q2 Loss Narrower Than Expected, Revenues Up

Amlogenyx Inc. Closes Successful Seed Funding Led by GordonMD® Global Investments LP

BEVERLY HILLS, Calif.--(BUSINESS WIRE)--GordonMD® Global Investments LP announced today that Amlogenyx Inc. has completed a seed funding round of USD 14 million. Amlogenyx, a subsidiary of Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE), is researching and developing novel gene therapies for Alzheimer's disease and other amyloid diseases. “I am pleased to collaborate with Amlogenyx; its promising Alzheimer's disease therapeutic has yielded exciting results in pursuing a therapy that has the pote.

Amlogenyx Inc. Closes Successful Seed Funding Led by GordonMD® Global Investments LP

Zacks Investment Research

Compared to Estimates, Ultragenyx (RARE) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Ultragenyx (RARE) Q2 Earnings: A Look at Key Metrics

Zacks Investment Research

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

Ultragenyx (RARE) came out with a quarterly loss of $1.52 per share versus the Zacks Consensus Estimate of a loss of $1.64. This compares to loss of $2.25 per share a year ago.

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

See News Rankings